ANABOLIC/CATABOLIC BALANCE IN SKELETAL MUSCLE OF MEN WITH PROSTATE CANCER

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our goal is to help older adults with cancer live healthier, more productive lives by protecting their muscles from the effects of cancer and/or cancer treatment. Androgen-deprivation therapy (ADT), a common treatment for prostate cancer, dramatically reduces the levels of the sex hormone testosterone in the blood to protect the prostate. ADT is beneficial in delaying the progression or recurrence of prostate cancer, but it also causes the loss of muscle. These changes in muscle are troubling because they cause muscle weakness and can impair quality of life. Furthermore, the age at which men are typically diagnosed with prostate cancer (50 - 80 y) is in itself associated with a loss of muscle mass and strength. Thus, ADT may cause premature frailty in older men. Despite the widespread use of ADT, little is known about the biological changes within muscle that explain muscle atrophy and weakness. Therefore, we will begin to determine how muscle biology changes within the first 3 months of ADT by measuring changes in specific genes important to muscle maintenance.